Patient, disease, donor, and transplantation characteristics of 266 haplo-HSCT recipients with acute leukemia according to diagnosis and disease status
| Characteristics . | Patients in remission at transplantation . | Patients in relapse at transplantation . | ||
|---|---|---|---|---|
| AML (n = 86) . | ALL (n = 61) . | AML (n = 87) . | ALL (n = 32) . | |
| Patient-related | ||||
| Median age at transplantation, y (range) | 37 (17-66) | 21 (16-51) | 36 (16-63) | 22 (16-46) |
| Female sex | 36 (42%) | 19 (31%) | 50 (57%) | 13 (41%) |
| Positive CMV serologic status at transplantation | 70 (88%) | 35 (63%) | 59 (76%) | 18 (75%) |
| Disease-related | ||||
| Status at transplantation | ||||
| CR1 | 25 (29%) | 24 (39%) | ||
| CR2 | 46 (53%) | 26 (42%) | ||
| CR3 | 15 (17%) | 11 (18%) | ||
| PIF | 36 (41%) | 8 (25%) | ||
| 1st relapse | 29 (33%) | 12 (37%) | ||
| 2nd relapse | 22 (25%) | 12 (37%) | ||
| Median WBC at diagnosis × 109/L | 8.8 (0.5-140) | 16.4 (0.6-289) | 26 (1.2-850) | 27.6 (2.7-400) |
| AML cytogenetics | ||||
| Good | 13 | 5 | ||
| Intermediate | 51 | 55 | ||
| Poor | 8 | 10 | ||
| ALL cytogenetics | ||||
| t(9;22) or t(4;11) | 27 | 13 | ||
| Normal or other | 21 | 7 | ||
| Previous autologous transplantation | 24 (28%) | 6 (10%) | 17 (20%) | 3 (9%) |
| Donor-related | ||||
| Age, y (range) | 38 (14-63) | 42 (14-75) | 36 (12-70) | 42 (17-61) |
| Female sex | 33 (39%) | 27 (44%) | 30 (35%) | 8 (25%) |
| Female to male | 16 (19%) | 19 (31%) | 10 (12%) | 4 (13%) |
| Positive CMV serologic status | 62 (79%) | 35 (66%) | 51 (67%) | 15 (63%) |
| Donor type | ||||
| Mother | 7 (9%) | 15 (31%) | 9 (12%) | 2 (8%) |
| Father | 7 (9%) | 10 (20%) | 14 (19%) | 10 (39%) |
| Brother | 20 (26%) | 10 (20%) | 19 (26%) | 9 (35%) |
| Sister | 11 (14%) | 9 (18%) | 5 (7%) | 3 (11%) |
| Others | 31 (41%) | 5 (10%) | 27 (37%) | 2 (8%) |
| Cousin | 9 | 2 | 5 | |
| Daughter | 9 | 1 | 11 | |
| Nephew | 1 | 0 | 1 | |
| Son | 8 | 2 | 11 | |
| Uncle | 1 | 0 | ||
| Unknown | 10 | 12 | ||
| HLA compatibility/total | ||||
| 2/6 | 18 (26%) | 23 (47%) | 23 (32%) | 7 (30%) |
| 3/6 | 49 (71%) | 23 (47%) | 49 (67%) | 16 (67%) |
| 4/6 | 2 (3%) | 3 (6%) | 1 (1%) | 1 (4%) |
| Transplantation-related | ||||
| Year of transplantation [median (range)] | 2002 (95-04) | 2002 (96-04) | 2001 (95-04) | 2000 (95-04) |
| Conditioning regimen based on TBI | 62 (74%) | 56 (92%) | 61 (71%) | 28 (87%) |
| ATG-based in vivo T-cell depletion | 74 (93%) | 51 (91%) | 80 (95%) | 27 (96%) |
| CD34+ ex vivo selection by Clinimacs | 55 (77%) | 42 (86%) | 63 (84%) | 17 (63%) |
| Cell dose | ||||
| No. of CD34+ × 106/kg [median (range)] | 10 (1.43-25) | 11.9 (3.69-30) | 9.4 (0-51) | 10.5 (2-22) |
| No. of CD3+ × 104/kg [median (range)] | 1 (0-6.4) | 1 (0-2.3) | 0.2 (0-3.6) | 0.2 (0.01-4) |
| Characteristics . | Patients in remission at transplantation . | Patients in relapse at transplantation . | ||
|---|---|---|---|---|
| AML (n = 86) . | ALL (n = 61) . | AML (n = 87) . | ALL (n = 32) . | |
| Patient-related | ||||
| Median age at transplantation, y (range) | 37 (17-66) | 21 (16-51) | 36 (16-63) | 22 (16-46) |
| Female sex | 36 (42%) | 19 (31%) | 50 (57%) | 13 (41%) |
| Positive CMV serologic status at transplantation | 70 (88%) | 35 (63%) | 59 (76%) | 18 (75%) |
| Disease-related | ||||
| Status at transplantation | ||||
| CR1 | 25 (29%) | 24 (39%) | ||
| CR2 | 46 (53%) | 26 (42%) | ||
| CR3 | 15 (17%) | 11 (18%) | ||
| PIF | 36 (41%) | 8 (25%) | ||
| 1st relapse | 29 (33%) | 12 (37%) | ||
| 2nd relapse | 22 (25%) | 12 (37%) | ||
| Median WBC at diagnosis × 109/L | 8.8 (0.5-140) | 16.4 (0.6-289) | 26 (1.2-850) | 27.6 (2.7-400) |
| AML cytogenetics | ||||
| Good | 13 | 5 | ||
| Intermediate | 51 | 55 | ||
| Poor | 8 | 10 | ||
| ALL cytogenetics | ||||
| t(9;22) or t(4;11) | 27 | 13 | ||
| Normal or other | 21 | 7 | ||
| Previous autologous transplantation | 24 (28%) | 6 (10%) | 17 (20%) | 3 (9%) |
| Donor-related | ||||
| Age, y (range) | 38 (14-63) | 42 (14-75) | 36 (12-70) | 42 (17-61) |
| Female sex | 33 (39%) | 27 (44%) | 30 (35%) | 8 (25%) |
| Female to male | 16 (19%) | 19 (31%) | 10 (12%) | 4 (13%) |
| Positive CMV serologic status | 62 (79%) | 35 (66%) | 51 (67%) | 15 (63%) |
| Donor type | ||||
| Mother | 7 (9%) | 15 (31%) | 9 (12%) | 2 (8%) |
| Father | 7 (9%) | 10 (20%) | 14 (19%) | 10 (39%) |
| Brother | 20 (26%) | 10 (20%) | 19 (26%) | 9 (35%) |
| Sister | 11 (14%) | 9 (18%) | 5 (7%) | 3 (11%) |
| Others | 31 (41%) | 5 (10%) | 27 (37%) | 2 (8%) |
| Cousin | 9 | 2 | 5 | |
| Daughter | 9 | 1 | 11 | |
| Nephew | 1 | 0 | 1 | |
| Son | 8 | 2 | 11 | |
| Uncle | 1 | 0 | ||
| Unknown | 10 | 12 | ||
| HLA compatibility/total | ||||
| 2/6 | 18 (26%) | 23 (47%) | 23 (32%) | 7 (30%) |
| 3/6 | 49 (71%) | 23 (47%) | 49 (67%) | 16 (67%) |
| 4/6 | 2 (3%) | 3 (6%) | 1 (1%) | 1 (4%) |
| Transplantation-related | ||||
| Year of transplantation [median (range)] | 2002 (95-04) | 2002 (96-04) | 2001 (95-04) | 2000 (95-04) |
| Conditioning regimen based on TBI | 62 (74%) | 56 (92%) | 61 (71%) | 28 (87%) |
| ATG-based in vivo T-cell depletion | 74 (93%) | 51 (91%) | 80 (95%) | 27 (96%) |
| CD34+ ex vivo selection by Clinimacs | 55 (77%) | 42 (86%) | 63 (84%) | 17 (63%) |
| Cell dose | ||||
| No. of CD34+ × 106/kg [median (range)] | 10 (1.43-25) | 11.9 (3.69-30) | 9.4 (0-51) | 10.5 (2-22) |
| No. of CD3+ × 104/kg [median (range)] | 1 (0-6.4) | 1 (0-2.3) | 0.2 (0-3.6) | 0.2 (0.01-4) |
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CR1, first complete remission; CR ≥ 2, second or subsequent complete remissions; and PIF, primary induction failure.